Kevin Charles Gorman
Chief Executive Officer at Neurocrine Biosciences Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Neurocrine Biosciences Inc.
Director · Chief Executive Officer
Xencor Inc.
Director
Chief executive roles
Neurocrine Biosciences Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Xencor Inc. | Grant or award | +10,302 | — | — |
| Jun 15, 2026 | Xencor Inc. | Open-market sale | −7,527 | $12.31 | $92,657 |
| May 19, 2026 | Neurocrine Biosciences Inc. | Option exercise | +205,088 | $43.24 | $8,868,005 |
| May 19, 2026 | Neurocrine Biosciences Inc. | Open-market sale | −245,088 | $154.33 | $37,824,431 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,604 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −3,024 | $124.12 | $375,339 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,377 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −2,901 | $124.12 | $360,072 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Grant or award | +63,724 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −34,380 | $124.12 | $4,267,246 |
| Jan 31, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,142 | — | — |
| Jan 31, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −2,845 | $136.06 | $387,091 |
| Aug 7, 2025 | Neurocrine Biosciences Inc. | Option exercise | +106,322 | $35.99 | $3,826,529 |
| Aug 7, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −106,322 | $126.41 | $13,440,164 |
| Jun 16, 2025 | Xencor Inc. | Open-market sale | −3,173 | $9.22 | $29,255 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.